Search
Sino-American Huadong, a subsidiary fully owned by a leading company, has recently secured a notification from the U.S. Food and Drug Administration (FDA) approving the clinical trial application for its proprietary HDM1002 tablet drug. HDM1002 is a small molecule full agonist targeting the GLP-1 receptor, engineered to enhance glucose tolerance, lower blood sugar levels, and facilitate weight loss. During the Phase I and Phase II clinical trials conducted in China, the drug enrolled over 800 participants and demonstrated notable efficacy in weight reduction and blood glucose management. This FDA approval does not immediately affect the company's current financial performance, and uncertainties persist regarding subsequent research and development efforts, as well as market competition dynamics.
-
C114 Communication Network -
Communication Home
